SST-0225 Topical Ibuprofen Cream — Competitive Intelligence Brief

SST-0225 Topical Ibuprofen Cream (SST-0225 Topical Ibuprofen Cream) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID. Area: Pain Management.

phase 3 NSAID Pain Management Small molecule

Target snapshot

SST-0225 Topical Ibuprofen Cream (SST-0225 Topical Ibuprofen Cream) — Strategic Science & Technologies, LLC. SST-0225 Topical Ibuprofen Cream works by reducing inflammation and relieving pain through the topical application of ibuprofen.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SST-0225 Topical Ibuprofen Cream TARGET	SST-0225 Topical Ibuprofen Cream	Strategic Science & Technologies, LLC	phase 3	NSAID
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Aleve	naproxen	Generic (originally Syntex)	marketed	NSAID	Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1	1976-01-01
Aspirin	acetylsalicylic acid	Bayer AG	marketed	NSAID, Antiplatelet agent	Gamma-glutamyltranspeptidase 1, Nicotinate phosphoribosyltransferase, Acid-sensing ion channel 3	1899-03-06
Acetaminophen and Ibuprofen	Acetaminophen and Ibuprofen	University of Manitoba	marketed	Analgesic/Antipyretic combination (NSAID + non-NSAID)	Prostaglandin synthesis pathway; COX-1/COX-2 enzymes
ropivacaine,morphine chloride,epinephrine,ketorolac	ropivacaine,morphine chloride,epinephrine,ketorolac	Jose Antonio Bernia Gil	marketed	Multimodal analgesic combination (local anesthetic + opioid + NSAID + sympathomimetic)	Sodium channels (ropivacaine), mu-opioid receptors (morphine), alpha/beta-adrenergic receptors (epinephrine), cyclooxygenase 1 and 2 (ketorolac)
ketorolac tromethamine 0.4%	ketorolac tromethamine 0.4%	Clinica Oftamologica Zona Sul	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID class)

1. Antibe Therapeutics Inc. · 3 drugs in this class
2. Iroko Pharmaceuticals, LLC · 3 drugs in this class
3. Organon and Co · 2 drugs in this class
4. Apsen Farmaceutica S.A. · 2 drugs in this class
5. Amneal Pharmaceuticals, LLC · 2 drugs in this class
6. Behar, Caren, M.D. · 2 drugs in this class
7. IDEA AG · 2 drugs in this class
8. Noven Pharmaceuticals, Inc. · 2 drugs in this class
9. HALEON · 2 drugs in this class
10. Pfizer · 2 drugs in this class